/
1.A 2 cm anterolateral incision was made at the 5th intercostal space, and the skin, subcutaneous tissue, and muscles were incised sequentially to enter the thoracic cavity.Thoracoscopic instruments were inserted through this incision. 2.Through the lung
Fragmented Left Lower Lobe Resection Specimen: 1.(Left) Lung (lower lobe): Central-type invasive adenocarcinoma, predominantly acinar pattern with focal papillary components. The tumor does not invade the pleura. 2.Bronchial stump and additionally submi
1.Fragmented left lower lobe resection specimen. A central-type tumor was identified 1 cm from the bronchial stump, measuring 4 × 3 × 2 cm. The cut surface appeared gray-white and firm. 2.Additionally submitted was a tracheal stump specimen, consisting o
Age：75
Gender：
Surgical Date：2021.07.14
Personal History：Healthy
Family history：Both parents deceased; siblings and children are healthy.
Smoking and drinking history：
Tumor size：4cmX3cmX2cm
Histological diagnosis：Mediastinoscopy was not performed. On July 5, 2021, bronchoscopy was performed under general anesthesia via laryngeal mask. The glottic structures were normal, and the carina was sharp. In the left lower lobe dorsal segment, the bronchial mucosa appeared
Immunohistochemistry：① TTF-1 (+), Napsin A (+), SP-B (+), CK7 (+), CK18 (+), Ki-67 (+, focal ~25%), MLH1 (+), PMS2 (+), MSH6 (+), MSH2 (+), P63 (−), p40 (−), CK5/6 (−), Syn (−), CgA (−**). ② ALK (D5F3, Ventana IHC): Positive (+).
Grade：II
TNM：T2bN2M0
Stage：IIIA
Gleason Score：/
Gleason Grade：/
Tumor content (%)：0.8
Necrosis content (%)：0
Treatment Regimen：Regular oral administration of alectinib capsules, 600 mg once daily
Disease Progression：Disease Progression 1:In August 2021, follow-up chest CT revealed a left-sided pleural effusion. In October 2021, repeat chest CT at an outside hospital showed bilateral pleural effusions, considered malignant pleural effusions secondary to recurrent pulm
Follow Up：Deceased(33M)
